Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02404168 · ClinicalTrials.gov registry record · Phase 4
BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT02404168 is a Phase 4 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 4 participants.
The verdict
NCT02404168, a Phase 4 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
The prior BEEP study involved patients being switched between brand and generic in a very structured manner. Other secondary comparisons were also made (i.e. any differences in adverse effects and seizure control). Some subjects were more disparate than other, in terms of generic being similar to brand. In this follow up study, BEEP subjects that showed disparate results will be tested again to assess reproducibility of disparate results.
Interventions
- DRUG lamotrigine (brand Lamictal)
- DRUG lamotrigine (generic Teva)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-07-07 |
| Est. Completion | 2016-04-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02404168
The ClinicalTrials.gov registry entry for NCT02404168 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lamotrigine (brand Lamictal) is the first listed.
NCT02404168 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02404168 about?
NCT02404168 is a clinical study titled "BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients". The prior BEEP study involved patients being switched between brand and generic in a very structured manner. Other secondary comparisons were also made (i.e. any differences in adverse effects and seizure control). Some subjects were more disparate than other, in terms of generic being similar to br...
What is the current status of trial NCT02404168?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2015-07-07. Estimated completion is 2016-04-06.
What interventions are being tested in trial NCT02404168?
The interventions under investigation include: lamotrigine (brand Lamictal) (DRUG), lamotrigine (generic Teva) (DRUG).
Who is sponsoring clinical trial NCT02404168?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.